| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net product sales | 169,061 | 154,688 | 125,249 | 141,517 |
| Cost of goods sold | 19,467 | 15,217 | 11,698 | 13,279 |
| Gross profit | 149,594 | 139,471 | 113,551 | 128,238 |
| Research and development | 23,415 | 60,848 | 27,839 | 26,160 |
| Selling, general, and administrative | 90,036 | 84,543 | 91,827 | 75,106 |
| Restructuring charges | 0 | 0 | - | 3,143 |
| Loss on impairment of assets | 0 | 1,702 | - | - |
| Depreciation and amortization | 1,874 | 1,852 | 1,837 | 2,170 |
| Total operating expenses | 115,325 | 148,945 | 121,503 | 106,579 |
| Income from operations | 34,269 | -9,474 | -7,952 | 21,659 |
| Interest income | 829 | 843 | 812 | 1,081 |
| Interest expense | 11,711 | 11,565 | 11,455 | 12,692 |
| Other income (expense) | 10,887 | 1,015 | 550 | -3,263 |
| Income (loss) before income tax | 34,274 | -19,181 | -18,045 | 6,785 |
| Income tax expense | 16,968 | 5,239 | 3,641 | 13,514 |
| Net income (loss) attributable to common stockholders | 17,306 | -24,420 | -21,686 | -6,729 |
| Net income (loss) attributable to common stockholders per common share basic (in dollars per share) | 0.06 | -0.08 | -0.07 | -0.02 |
| Net income (loss) attributable to common stockholders per common share diluted (in dollars per share) | 0.06 | -0.08 | -0.07 | -0.02 |
| Weighted average common shares outstanding - basic (in shares) | 308,468,423 | 308,254,256 | 307,689,207 | 304,690,596 |
| Weighted average common shares outstanding - diluted (in shares) | 310,433,494 | 308,254,256 | 307,689,207 | 304,690,596 |
AMICUS THERAPEUTICS, INC. (FOLD)
AMICUS THERAPEUTICS, INC. (FOLD)